Meeting
2023 ASCO Annual Meeting
Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.
Authors
Jason Silberman
Massachusetts General Hospital, Boston, MA
Jason Silberman , Alexandra Bercow , Allison Ann Gockley , Eric L Eisenhauer , Rachel Sisodia , Thomas Christopher Randall , Alexander Melamed , Amy Bregar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5581)
DOI
10.1200/JCO.2023.41.16_suppl.5581
Abstract #
5581
Poster Bd #
276
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Randomized phase II study of 3 versus 6 courses of neoadjuvant carboplatin-paclitaxel chemotherapy in stage IIIC or IV epithelial ovarian cancer.
First Author: Claudio Zamagni
Poster
2021 ASCO Annual Meeting
The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.
First Author: Rachel Soyoun Kim
Poster
2021 ASCO Annual Meeting
Circulating tumor DNA as a noninvasive marker of resectability in ovarian carcinomas.
First Author: Roxane Mari
Poster
2019 ASCO Annual Meeting
Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.
First Author: Gwenael Ferron